Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab

Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...

Full description

Bibliographic Details
Main Authors: Smaranda Maier, Mihaela Simu, Adina Hutanu, Laura Barcutean, Septimiu Voidazan, Zoltan Bajko, Anca Motataianu, Irina Lata, Rodica Balasa
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Brain Sciences
Subjects:
Online Access:https://www.mdpi.com/2076-3425/10/11/802

Similar Items